馬 舒荷（Shuhe Ma）

研究概要

・Aging influence on Kupffer cells of healthy and diseased liver
・Onset mechanism of certain human liver disease

From hepatoblastoma to primary sclerosing cholangitis (PSC), liver diseases are affecting people in a variety of age groups. However, characteristics of specific immune cells across normal healthy liver and diseased livers in different age groups remains uncovered. Although KC attributes 5-10% in normal liver, and up to 40% in some diseased liver, most of its function, and its connection to other types of immune or liver cells remains unclear. Thus, research on how KC contributes to liver diseases and how they collaborate with other cells in the liver might reveal new therapeutic strategies to liver diseases.

<!–

Non-T and non-B cells in primary biliary cholangitis and primary sclerosing cholangitis

Primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) are serious liver diseases affecting people worldwide. Besides T cells and B cells, macrophages, monocytes, and other immune cells also contribute to these diseases. However, proportions and functions of these non-T and non-B cells in human are not much known. Thus, research on how each kind of non-T and non-B cells contributes to these diseases and how they collaborate with each other might reveal new therapeutic strategies to PBC and PSC.

Human study in exploring the details of non-T and non-B immune cells activated in PBC and PSC comparing with healthy control. Functional analysis of Kupffer cells, monocytes, dendritic cells (DC), antigen-presenting cells (APC) as well as granulocytes will be covered. Also, the functional differences between the two Kupffer cell clusters, as well as the origin of Kupffer cells of PBC or PSC are of interests.

–>

略歴

Shuhe Ma got her bachelor degree in Biotechnology at Harbin Institute of Technology (2014), and earned her master degree in Biology at Leiden university (2016). From 2017, she joined the doctoral course at the Graduate School of Medicine in Kyoto University, and undertook postdoctoral training at the Dept. of Immunology (2020-2021) as a postdoc. She joined ASHBi at 2022.

論文

Ma S, Murakami K, Tanaka K, Hashimoto M, Tanaka M, Kitagori K, Akizuki S, Nakashima R, Yoshifuji H, Ohmura K, Morinobu A, Mimori T. Fatostatin ameliorates inflammation without affecting cell viability. FEBS Open Bio. 2022 Jan 11. doi:10.1002/2211-5463.13364. Epub ahead of print. PMID: 35015380.

Ma S, Murakami K, Saito R, Ito H, Murata K, Nishitani K, Hashimoto M, Tanaka M, Taniguchi M, Kitagori K, Akizuki S, Nakashima R, Yoshifuji H, Ohmura K, Morinobu A, Mimori T. Increased Ratio of CD14⁺⁺CD80⁺ Cells/CD14⁺⁺CD163⁺ Cells in the Infrapatellar Fat Pad of End-Stage Arthropathy Patients. Front Immunol. 2021 Nov 26;12:774177. doi:10.3389/fimmu.2021.774177. PMID: 34899727; PMCID: PMC8662627.

Nakagami Y, Sugihara G, Nakashima N, Hazama M, Son S, Ma S, Matsumoto R, Murai T, Ikeda A, Murakami K. Anti-PDHA1 antibody is detected in a subset of patients with schizophrenia. Sci Rep. 2020 May 13;10(1):7906. doi:10.1038/s41598-020-63776-0. PMID: 32404964; PMCID: PMC7220915.